Vertex Pharmaceuticals (NQ:VRTX)

500.27 -3.23 (-0.64%)

Delayed Quote Updated: 1:23 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

77 78 Next >

Vertex Grapples With Bearish Chart As Death Cross Emerges ↗

January 07, 2025

Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months.

Via Benzinga

If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today ↗

January 07, 2025

Via Benzinga

2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025

January 07, 2025

Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space.

Via MarketBeat

Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip ↗

December 28, 2024

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

December 26, 2024

Via Benzinga

Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip ↗

December 26, 2024

Via The Motley Fool

Top Stock Reports For T-Mobile, Toyota Motor & Vertex Pharmaceuticals ↗

December 24, 2024

Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc., Toyota Motor Corp., and Vertex Pharmaceuticals Inc., as well as two micro-cap stocks BK...

Via Talk Markets

Topics Stocks / Equities

3 No-Brainer Stocks to Buy on the Latest Sell-Off ↗

December 24, 2024

Via The Motley Fool

Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13

December 23, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst ↗

December 23, 2024

Vertex Pharmaceuticals announced FDA approval for Alyftrek, which expands the company's CF franchise to address around 6,000 such patients.

Via Benzinga

Microsoft To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Monday ↗

December 23, 2024

Via Benzinga

Novo Nordisk, Super Micro Computer And Arm Are Among Top Large Cap Losers Last Week (December 16-20): Are The Others In Your Portfolio? ↗

December 22, 2024

11 worst-performing large-cap stocks: NVO, VRTX, XPO, SMCI, NU, ARM, MU, PAYC, CTAS, WBD, MNDY. Blame fiscal spending package, Fed rate hike, weak earnings.

Via Benzinga

Topics Economy

Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025? ↗

December 22, 2024

Via The Motley Fool

3 Fantastic Stocks That Could Enjoy a Santa Claus Rally ↗

December 21, 2024

Via The Motley Fool

My Top 10 Stocks to Buy for 2025 ↗

December 21, 2024

Via The Motley Fool

Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock ↗

December 20, 2024

The FDA signed off on Vertex's newest cystic fibrosis treatment. But it might not help beleaguered Vertex stock.

Via Investor's Business Daily

Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis

December 20, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants

December 20, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Stock Market Tumbles, Treasury Yields Soar On Fed Rate Outlook: Weekly Review ↗

December 20, 2024

Micron, Vertex, Novo Nordisk and Nike were notable losers on news.

Via Investor's Business Daily

Topics Economy

Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study? ↗

December 20, 2024

The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future.

Via Investor's Business Daily

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 19, 2024

Via Benzinga

Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data? ↗

December 19, 2024

Vertex Pharmaceuticals' suzetrigine reduced pain in Phase 2 trials for lumbosacral radiculopathy. Plans for Phase 3 trials follow regulatory discussions.

Via Benzinga

Vertex Plunges 10% After Its Non-Opioid Pain Drug Flops In Lower Back Pain ↗

December 19, 2024

The company says there was variability among placebo responses at various sites.

Via Investor's Business Daily

Vertex Non-Opioid Drug Doesn't Best Placebo In Back Pain Study. The Stock Is Plunging. ↗

December 19, 2024

Vertex Pharmaceuticals' drug reduced back pain significantly.

Via Investor's Business Daily

Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy

December 19, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

2 Unstoppable Stocks to Buy and Hold for the Next Decade ↗

December 19, 2024

Via The Motley Fool

2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio? ↗

December 17, 2024

Via The Motley Fool

Tesla To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Monday ↗

December 16, 2024

Via Benzinga

Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030 ↗

December 16, 2024

Via The Motley Fool

3 Unstoppable Stocks to Buy Right Now ↗

December 15, 2024

Via The Motley Fool

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

77 78 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.